RNS Number : 4959U
Genus PLC
02 August 2022

2 August 2022

Genus plc

('Genus' or the 'Company')

Appointment of Joint Corporate Broker

Genus plc (LSE: GNS), a leading global animal genetics company, is pleased to announce the appointment of HSBC Bank plc ("HSBC") as its Joint Corporate Broker alongside Peel Hunt and Liberum, with immediate effect. The appointment is in addition to HSBC's existing role as Financial Adviser.

For further information, please contact:

Genus plc Tel: 01256 345970
Stephen Wilson, Chief Executive Officer
Alison Henriksen, Chief Financial Officer

HSBC Bank plc - Joint Broker and Financial Adviser Tel: 020 7991 8888
Adam Miller / James Hopton / Keith Welch

Buchanan Tel: 0207 466 5000
Charles Ryland / Chris Lane / Sophie Wills

This announcement is available on the Genus website www.genusplc.com

About Genus

Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Genus' worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFLFEVTLILIIF